WILMINGTON, Del.--(BUSINESS WIRE)--
Rigrodsky & Long, P.A.:
- Do you own shares of ARMO BioSciences, Inc. (NASDAQ GS: ARMO)?
- Did you purchase any of your shares prior to May 10, 2018?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQ GS: ARMO) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Eli Lilly and Company (“Lilly”) (NYSE: LLY) in a transaction valued at approximately $1.6 billion. Under the terms of the agreement, shareholders of ARMO will receive $50.00 in cash for each share of ARMO common stock.
If you own common stock of ARMO and purchased any shares before May 10, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail at [email protected].
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware, Garden City, New York, and San Francisco, California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180510005941/en/
